Mette Yilmaz

4.7k total citations
45 papers, 1.3k citations indexed

About

Mette Yilmaz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Mette Yilmaz has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in Mette Yilmaz's work include Colorectal Cancer Treatments and Studies (18 papers), Gastric Cancer Management and Outcomes (15 papers) and Pancreatic and Hepatic Oncology Research (11 papers). Mette Yilmaz is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Gastric Cancer Management and Outcomes (15 papers) and Pancreatic and Hepatic Oncology Research (11 papers). Mette Yilmaz collaborates with scholars based in Denmark, Norway and Netherlands. Mette Yilmaz's co-authors include Benny Vittrup Jensen, Per Pfeiffer, Julia S. Johansen, Stig E. Bojesen, Niels Henrik Holländer, Svend Erik Nielsen, Christian Dehlendorff, Jon Kroll Bjerregaard, Dan Calatayud and Kaspar René Nielsen and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mette Yilmaz

45 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mette Yilmaz Denmark	19	796	496	445	297	230	45	1.3k
Melanie Mackean United Kingdom	20	873 1.1×	301 0.6×	563 1.3×	469 1.6×	236 1.0×	48	1.7k
Júlio Oliveira Portugal	18	502 0.6×	208 0.4×	283 0.6×	412 1.4×	234 1.0×	41	1.1k
Enzo Maria Ruggeri Italy	22	681 0.9×	279 0.6×	274 0.6×	535 1.8×	354 1.5×	103	1.4k
Elena Maccaroni Italy	17	545 0.7×	287 0.6×	247 0.6×	299 1.0×	101 0.4×	54	944
Lara Pijuán Spain	20	571 0.7×	311 0.6×	307 0.7×	680 2.3×	168 0.7×	74	1.3k
Martha Donoghue United States	16	696 0.9×	285 0.6×	247 0.6×	400 1.3×	154 0.7×	27	1.2k
Hui‐Li Wong Australia	16	987 1.2×	665 1.3×	245 0.6×	439 1.5×	187 0.8×	104	1.5k
Matthew Burge Australia	19	703 0.9×	215 0.4×	218 0.5×	224 0.8×	170 0.7×	123	1.1k
Daniela Kandioler Austria	23	835 1.0×	529 1.1×	622 1.4×	350 1.2×	351 1.5×	55	1.7k
Wenzhuo He China	19	878 1.1×	325 0.7×	241 0.5×	279 0.9×	296 1.3×	84	1.3k

Countries citing papers authored by Mette Yilmaz

Since Specialization

Citations

This map shows the geographic impact of Mette Yilmaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mette Yilmaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mette Yilmaz more than expected).

Fields of papers citing papers by Mette Yilmaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mette Yilmaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mette Yilmaz. The network helps show where Mette Yilmaz may publish in the future.

Co-authorship network of co-authors of Mette Yilmaz

This figure shows the co-authorship network connecting the top 25 collaborators of Mette Yilmaz. A scholar is included among the top collaborators of Mette Yilmaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mette Yilmaz. Mette Yilmaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schou, Jakob Vasehus, Jakob Lykke, Dorte Nielsen, et al.. (2025). The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer. Cancer Treatment and Research Communications. 43. 100907–100907. 2 indexed citations

Bæksgaard, Lene, Mette Yilmaz, Marianne Nordsmark, et al.. (2024). TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial. EClinicalMedicine. 70. 102521–102521. 1 indexed citations

Bye, Asta, Sture Falkmer, Henrik Højgaard Rasmussen, et al.. (2023). The effect of nutritional interventions in acute radiation-induced diarrhoea in patients with primary pelvic cancer: A systematic review. Critical Reviews in Oncology/Hematology. 188. 104038–104038. 2 indexed citations

Yilmaz, Mette, et al.. (2022). New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy. Cancer Treatment and Research Communications. 31. 100543–100543. 5 indexed citations

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2021). Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas. 50(5). 685–695. 3 indexed citations

Yilmaz, Mette, Sture Falkmer, Laurids Østergaard Poulsen, et al.. (2020). Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer. 144. 72–80. 19 indexed citations

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2020). Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. European Journal of Cancer. 129. 50–59. 15 indexed citations

Palshof, Jesper Andreas, Estrid Høgdall, Tim Svenstrup Poulsen, et al.. (2020). ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 21(14). 5027–5027. 8 indexed citations

Pfeiffer, Per, Mette Yilmaz, Sören Möller, et al.. (2020). TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. The Lancet Oncology. 21(3). 412–420. 150 indexed citations

10.

Ladekarl, Morten, Per Pfeiffer, Mette Yilmaz, et al.. (2019). The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Acta Oncologica. 58(6). 864–871. 20 indexed citations

11.

Chen, Inna M., Astrid Z. Johansen, Christian Dehlendorff, et al.. (2019). Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention. 29(1). 176–184. 12 indexed citations

12.

Poulsen, Laurids Østergaard, et al.. (2018). Is the accuracy of preoperative MRI stage in rectal adenocarcinoma influenced by tumour height?. Acta Oncologica. 57(6). 728–734. 10 indexed citations

13.

Palshof, Jesper Andreas, Estrid Høgdall, Tim Svenstrup Poulsen, et al.. (2017). Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer. 17(1). 48–48. 17 indexed citations

14.

Poulsen, Laurids Østergaard, et al.. (2016). Is the accuracy of preoperative MRI stage in rectal carcinoma influenced by tumor height?. Journal of Clinical Oncology. 34(4_suppl). 514–514. 1 indexed citations

15.

Spindler, Karen‐Lise Garm, Niels Pallisgaard, Ane Appelt, et al.. (2015). Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. European Journal of Cancer. 51(17). 2678–2685. 40 indexed citations

16.

Boige, Valérie, Marc Vincent, Jan Stoehlmacher, et al.. (2015). DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 3584–3584. 1 indexed citations

17.

Mol, Linda, et al.. (2015). The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. Journal of Clinical Oncology. 33(15_suppl). TPS3630–TPS3630. 3 indexed citations

18.

Schou, Jakob Vasehus, Simona Rossi, Benny Vittrup Jensen, et al.. (2014). miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. PLoS ONE. 9(6). e99886–e99886. 68 indexed citations

19.

Schultz, Nicolai A., Ib Jarle Christensen, Jens Werner, et al.. (2013). Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS ONE. 8(6). e67059–e67059. 29 indexed citations

20.

Pfeiffer, Per, et al.. (2007). Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncologica. 46(5). 697–701. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact